NCT05805631View on ClinicalTrials.gov

Intrathecal Pemetrexed for Leptomeningeal Metastasis in EGFR-Mutant NSCLC

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

23

Participants

Timeline

Start Date

June 1, 2024

Primary Completion Date

June 1, 2026

Study Completion Date

June 1, 2027

Conditions

Carcinoma, Non-Small-Cell LungEpidermal Growth Factor ReceptorLeptomeningeal Metastasis

Interventions

DRUG

Pemetrexed

Intrathecal Pemetrexed

All Listed Sponsors

lead

Taipei Veterans General Hospital, Taiwan

OTHER_GOV